Eckert & Ziegler Annual Financial Statement 2017: Profit and net liquidity reach new records, sales stable.
2018-03-22 / Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in in isotope-related applications in medicine, science and industry, was able to push profits and net liquidity to new records in the 2017 fiscal year, while keeping sales stable. Net income after taxes and non-controlling interests from continuing and discontinued operations increased by 53.9% from EUR 9.6 million to EUR 14.7 million. Earnings per share increased by EUR 0.97 per share to EUR 2.78 per share. Continuing operations accounted for EUR 2.19 per share, an increase of approximately 14% on the previous year.
By the reporting date, the liquid assets of the Group increased by 21 million to nearly EUR 59 million. Since in the year under review a substantial reduction in loan liabilities was achieved at the same time, net liquidity, i.e. the difference between cash holdings and liabilities, increased by 125% or EUR 31 million to EUR 56 million.
Including the discontinued operations, sales of EUR 144.8 million were achieved in the year under review (previous year: EUR 138.0 million). Looking only at the continuing operations, sales increased by around 16% from EUR 119.9 million in the previous year to EUR 138.6 million. The acquisition of the Gamma-Service Group in May 2017 essentially compensated for the decline in revenue from the sale of the Cyclotron division.
The largest segment, Isotope Products, recorded the largest increase in sales by EUR 13.5 million to EUR 89.7 million. The acquisition of Gamma-Service Group companies in May 2017 contributed approximately EUR 11.3 million.
In the Radiation Therapy segment, sales increased by EUR 1.0 million year-on-year to EUR 25.9 million. Sales of SagiNova® continued to fall short of expectations due to the poor economic situation in the target markets of South America and Russia. Thanks to a good fourth quarter, however, the sales from the previous year were exceeded. Overall, EUR 0.8 million more was generated in the area of tumor irradiation systems than in 2016. A further EUR 0.3 million in revenue was generated in the area of seeds, eye applicators and others.
In the Radiopharma segment, revenues excluding discontinued operations increased from EUR 21.8 million to EUR 26.6 million, driven in particular by the demand for pharmaceutical radioisotopes. The Cyclotron division was sold in May 2017 and is accordingly reported as a discontinued operation; it was therefore not included in the analysis of sales development.
For the fiscal year 2018, an increase in sales to about EUR 155.0 million and an EBIT of around EUR 18.5 million are expected. This should result in a consolidated profit of about EUR 11.6 million or EUR 2.20 per share. The forecasts are subject to an exchange rate of no more than USD 1.15 per EUR.
The income statement, balance sheet and cash flow statement for the past fiscal year can be found at https://www.ezag.com/home/investors/reports/
The audited annual financial statements will be posted there on March 29, 2018.
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.